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Abstract The aim of the study was to investigate health
status in patients with myotonic dystrophy type 2 (DM2)
and determine its relationship to pain and fatigue. Data
on health status (SF-36), pain (MPQ) and fatigue (CIS-
fatigue) were collected for the Dutch DM2 population
(n = 32). Results were compared with those of sex- and
age-matched adult-onset myotonic dystrophy type 1 (DM1)
patients. In addition, we compared the obtained scores on
health status of the DM2 group with normative data of the
Dutch general population (n = 1742). Compared to DM1,
the SF-36 score for bodily pain was signiﬁcantly (p = 0.04)
lower in DM2, indicating more body pain in DM2. DM2 did
not differ from DM1 on any other SF-36 scales. In com-
parison to the Dutch population, DM2 patients reported
lower scores (indicating worse clinical condition) on the
physical functioning, role functioning-physical, bodily
pain, general health, vitality, social functioning, and role
functioning-emotional scales (p\0.01 on all scales). The
difference was most profound for the physical functioning
scale. In the DM2 group the severity of pain was signiﬁ-
cantly correlated with SF-36 scores for bodily pain
(p = 0.003). Fatigue was signiﬁcantly correlated with the
SF-36 scores for role functioning-physical (p = 0.001),
general health (p = 0.02), and vitality (p = 0.02). The
impact of DM2 on a patients’ physical, psychological and
social functioning is signiﬁcant and as high as in adult-onset
DM1 patients. From the perspective of health-related
quality of life, DM2 should not be considered a benign
disease. Management of DM2 patients should include
screening for pain and fatigue. Symptomatic treatment of
pain and fatigue may decrease disease impact and help
improve health status in DM2, even if the disease itself
cannot be treated.
Keywords Myotonic dystrophy type 2  Health status 
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Introduction
Myotonic dystrophy type 2 (DM2) is a dominantly inherited
multisystem disease with muscle pain, weakness, myotonia,
early-onset cataracts, and involvement of other organs,
including the heart, brain, and gastro-intestinal system
[1–3]. The genetic origin was clariﬁed in 2001 and consists
of a CCTG expansion repeat located in intron 1 of the zinc
ﬁnger protein 9 (ZNF9) gene on chromosome 3q21 [4].
The phenotype and clinical course of DM2 are generally
more favorable than myotonic dystrophy type 1 (DM1), the
most common type of muscular dystrophy in adult life [5].
The severe congenital form in DM1 is absent in DM2, and
evidence of anticipation is less striking in DM2. Muscle
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8]. In various neuromuscular disorders, including non-
dystrophic myotonic syndromes, pain has been shown to be
a prominent symptom related to health status [9, 10].
Fatigue, another dominant symptom in neuromuscular
diseases, is correlated with lower health status in DM1 and
non-dystrophic myotonic syndromes [10, 11].
Although DM2 is a chronic disorder, up to now no
studies have assessed health status in DM2 patients, where
health status is deﬁned as the impact of a disease on a
patients’ physical, psychological and social functioning
[12]. Likewise, no data are available about the contribution
of pain and fatigue on DM2 patients’ health status.
In this nationwide study we investigated health status, as
measured with the SF-36, in patients with genetically
conﬁrmed DM2. We chose the SF-36 because of its
extensive use both in general population surveys and in
patient studies, and its validated translation in Dutch [13,
14]. We also examined the presence of pain (McGill Pain
Questionnaire) and fatigue (CIS-fatigue scale), and tested
the hypothesis that both these two symptoms correlate with
health status. Results were compared with those of sex- and
age-matched adult-onset DM1 patients, and with data on
health status (SF-36 scores) for the Dutch general popu-
lation [15].
Patients and methods
Patients
All known Dutch DM2 patients (n = 32) were approached
to participate and 29 (91%) responded and completed the
questionnaires in their home. All Dutch districts were
represented in the sample and patients were treated in
various hospitals throughout the Netherlands. As disease
controls, we included 29 sex- and age-matched patients
with adult-onset DM1. Both DM2 and DM1 patient groups
were retrieved from CRAMP, the Dutch neuromuscular
database [16]. Inclusion criteria were a genetically con-
ﬁrmed diagnosis of DM2 or DM1 at least 1 year prior to
this survey and an age of 18 years and older. There were no
exclusion criteria. The study was approved by the local
ethical committee and all patients provided written
informed consent.
Data collection
SF-36
Health status was assessed using the Dutch version of the
SF-36 health survey. The SF-36 comprises four physical
health scales (physical functioning, role limitations due to
physical problems, bodily pain, and general health per-
ception) and four mental health scales (vitality, social
functioning, role limitations due to emotional problems,
and mental health) [17]. Items are summed per scale and
transformed into scores between 0 and 100, with higher
scores indicating better function or less bodily pain [17].
The SF-36 has been used to assess health status in many
different conditions, including myotonic dystrophy type 1,
inclusion body myositis and late-onset Pompe disease
[11, 18, 19].
MPQ
Pain intensity and analgesic use were assessed with the
McGill Pain Questionnaire (MPQ). The MPQ is widely
used, well validated and reliable [20, 21]. Pain intensity
was scored on a 100 mm horizontal visual analogue scale
(VAS), where 0 indicates no pain and 100 indicates pain as
bad as could be. The main outcome measure for pain was
the magnitude of pain at the current moment.
CIS-fatigue
The presence and level of fatigue was assessed using the
‘fatigue severity’ subscale of the Checklist Individual
Strength (CIS) [22]. The CIS measures the experience of
fatigue-associated problems during the previous 2 weeks.
The CIS-fatigue severity subscale contains eight items
scored on a 7-point Likert scale. Scores can range between
8 and 56 with higher scores indicating higher levels of
fatigue and scores of 35 or more are considered to indicate
severe fatigue [22, 23].
Statistical analysis
Original data on health status for the Dutch general
population, including SF-36 scores, age and sex, were
available for analysis (n = 1,742) [15]. The clinimetric
performance of the SF-36 in the Dutch general popula-
tion has been reported previously [15]. Differences in SF-
36 scores between DM2 and the general population and
between DM1 and the population were tested by analysis
of covariance (ANCOVA) with adjustment for age and
sex. Differences in SF-36 scores between DM2 and DM1
patients were tested with t-tests. Pearson correlations
were computed to measure the relationship between
patient characteristics and SF-36 scales. p values below
0.05 were considered to be signiﬁcant. Numerical vari-
ables are reported as mean ± standard deviation (range).
Categorical data are reported as number (percentage of
total).
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Study population
Of the 32 DM2 patients invited to participate, 29 patients
(91%) from 13 families participated in the study. Three
DM2 patients did not consent and did not specify their
reasons for non-participation. The disease control group
existed of 29 sex- and age-matched adult-onset DM1
patients from 25 families. There were no missing values in
the patient groups. The percentage of missing values for
each SF-36 scale in the Dutch general population group
(n = 1,742) was lowest for the social functioning and
bodily pain scales (0.4%, n = 7, for each) and highest for
the role functioning-emotional scale (2.9%, n = 51).
Demographic characteristics of the three groups are listed
in Table 1. Age, sex, age of onset, disease duration and
BMI did not differ signiﬁcantly between the two patient
groups.
Health status (SF-36)
Table 2 presents raw (unadjusted) group means on the
SF-36 scales for DM2 and DM1 patients. To compare the
health status of DM2 and DM1 with the general population,
SF-36 scores were adjusted for age and sex. Figure 1
presents the adjusted mean SF-36 scores in DM2, DM1 and
the general population.
DM2 and DM1 both scored signiﬁcantly lower than the
general population on physical functioning (p = 0.001, for
both). DM2 reported a signiﬁcantly lower score on the
bodily pain scale (indicating a higher level of pain) than the
population (p = 0.005), whereas DM1 did not differ from
the population on the bodily pain scale (p = 0.97).
The scales role functioning-physical, general health,
social functioning, role functioning-emotional, and vitality
yielded a similar pattern of results. On each of these scales,
DM2 scored signiﬁcantly lower than the population
(p\0.01). Likewise, DM1 scored signiﬁcantly lower than
the population on each of these ﬁve scales (p\0.04). The
DM2 score on the mental health scale did not differ sig-
niﬁcantly (p = 0.06) from the Dutch normative sample.
Comparisons of SF-36 scales between the patient groups
revealed that DM2 scored signiﬁcantly lower than DM1 on
bodily pain (p = 0.04), indicating a higher level of pain in
DM2. There were no signiﬁcant differences between the
patient groups on the remaining SF-36 scales (p[0.10).
In DM2 age was not correlated with age of onset, SF-36
scores, pain (VAS momentary and VAS maximal) scores,
and CIS-fatigue. Age of onset was correlated with SF-36
bodily pain score (r = 0.39, p = 0.04) in DM2.
In contrast, in DM1 age was correlated with age of onset
(r = 0.71, p\0.001), SF-36 scores physical functioning
(r =- 0.50, p = 0.006), social functioning (r =- 0.51,
p = 0.005), mental health (r =- 0.43, p = 0.02), vitality
(r =- 0.39, p = 0.037), bodily pain (r =- 0.39, p =
0.039), general health (r =- 0.41, p = 0.027) and CIS-
fatigue score (r = 0.48, p\0.01). Furthermore, there was
an association between age of onset and SF-36 social
functioning (r =- 0.41, p = 0.03) and mental health
scores (r =- 0.41, p = 0.03).
Pain (MPQ)
Mean VAS momentary and maximum pain scores per
patient group are shown in Table 2. Twenty-three out of
the 29 DM2 patients (79%) reported pain complaints, 6
DM2 patients (21%) reported that they had no pain at all.
Eight DM2 patients (28%) used analgesics, speciﬁcally
opioids (3 patients, 10%), NSAIDs (2 patients, 7%), para-
cetamol (2 patients, 7%), and amitriptyline (1 patient, 3%).
Thirteen DM1 patients (45%) reported having pain, the
other 16 DM1 patients (55%) reported that they had no
pain at all. Seven DM1 patients (24%) used analgesics,
speciﬁcally NSAIDs (2 patients, 7%), paracetamol (5
patients, 17%), and amitriptyline (1 patient, 3%).
DM2 scored signiﬁcantly higher than DM1 on VAS
maximum pain (t (56) = 3.07, p = 0.003), indicating more
pain in DM2. Although DM2 scored higher than DM1 on
VAS momentary pain, this difference did not achieve
signiﬁcance (t (56) = 1.79, p = 0.079).
In both DM2 and DM1 VAS momentary scores were
correlated with VAS maximum (DM2: r = 0.70, p\
0.001, DM1: r = 0.81, p\0.001), SF-36 score bodily pain
Table 1 Characteristics of
patients with DM2 and DM1,
and of the general population
Data presented as
mean ± standard deviation
(range) or as N (%)
BMI Body Mass Index
DM2 DM1 Dutch general
population [15]
N 29 29 1,742
Age (years) 53.2 ± 12.1 (28–71) 52.8 ± 12.0 (28–72) 47.6 ± 18.0 (16–94)
Females 20 (69%) 20 (69%) 761 (44%)
BMI (kg/m
2) 25.1 ± 3.8 (18.8–36.0) 25.7 ± 3.5 (16.5–30.9) –
Age of onset (years) 35.9 ± 13.4 (12–67) 37.2 ± 13.7 (15–61) –
Disease duration 17.3 ± 15.0 (2–57) 17.0 ± 9.9 (1–38) –
1822 J Neurol (2011) 258:1820–1826
123(DM2: r =- 0.40, p = 0.03, DM1: r =- 0.71, p\0.01)
and CIS-fatigue score (DM2: r = 0.39, p = 0.04, DM1:
r = 0.43, p = 0.02). In DM1 VAS momentary scores also
correlated with SF-36 score social functioning (r =- 0.51,
p\0.01) and role functioning-emotional (r =- 0.40,
p = 0.03).
Fatigue (CIS-fatigue)
Mean fatigue scores per patient group are shown in
Table 2. Nineteen of the 29 DM2 patients (66%) and 25 out
of the 29 DM1 patients (86%) reported severe fatigue.
Although there was a higher average level of fatigue in
DM1 patients in comparison to DM2, this difference did
not achieve signiﬁcance (p = 0.059).
In DM2 CIS-fatigue scores were correlated with SF-36
scores role functioning-physical (r =- 0.58, p = 0.001),
vitality (r =- 0.44, p = 0.016) and general health (r =
-0.42, p = 0.02), as well as with VAS maximum
(r = 0.70, p\0.001). In DM1 CIS-fatigue scores were
signiﬁcantly correlated with all of the SF-36 scales except
for the scale mental health (Table 3).
Discussion
In this nationwide study we found that DM2 patients scored
signiﬁcantly lower than the Dutch general population on
Table 2 Mean scores of DM2
patients and DM1 patients on
the outcome measures
Data presented as mean (SD) or
N (%)
DM2 DM1 p value
DM2–DM1
Health status (SF-36)
Physical health
Physical functioning 38.4 (27.9) 50.7 (28.6) 0.11
Role functioning-physical 37.1 (35.7) 50.9 (41.4) 0.18
Bodily pain 57.6 (24.6) 73.1 (31.6) 0.04
General health 42.4 (23.1) 41.7 (19.7) 0.90
Mental health
Vitality 45.9 (23.0) 39.1 (16.0) 0.20
Social functioning 69.1 (29.5) 70.0 (24.7) 0.90
Role functioning-emotional 58.5 (44.3) 65.4 (43.2) 0.55
Mental health 69.7 (22.9) 68.0 (20.8) 0.77
Pain (MPQ)
Pain (%) 23 (79.3) 13 (44.8) 0.014
VAS-momentary pain (mm) 23.6 (22.5) 13.1 (21.8) 0.079
VAS-maximum pain (mm) 56.3 (34.9) 27.8 (36.0) 0.003
Fatigue (CIS)
Severe fatigue (%) 19 (65.5) 25 (86.2) 0.066
CIS-fatigue score 38.7 (13.1) 44.3 (8.7) 0.058
0
50
100
BP
PF
RP
GH
VT
SF
RE
MH
DM2 DM1 population
Fig. 1 Health status in Dutch myotonic dystrophy type 2 patients
compared to the Dutch general population. Solid line DM2 (n = 29).
Dotted line DM1 (n = 29). Dashed line general population
(n = 1,742). Values are mean scores for SF-36 scales, adjusted for
age and sex. The center of the graph represents the lowest possible
score on each scale. BP bodily pain, PF physical functioning, RP role
functioning-physical, GH general health, VT vitality, SF social
functioning, RE role functioning-emotional, MH mental health
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123seven of the eight physical and mental health scales of the
SF-36. SF-36 scores in DM2 were comparable to those of
adult-onset DM1 patients on all SF-36 scales except for
bodily pain scale. DM2 scored signiﬁcantly lower than
DM1 on the bodily pain scale, indicating more body pain in
DM2. These results demonstrate that DM2 has a high dis-
ease impact on physical as well as on mental health func-
tioning. This impact is at least comparable to that of adult-
onset DM1. Until now, DM2 was considered a benign
disease, mainly because of the more favorable phenotype
and clinical course of DM2 in comparison to DM1 [5].
However, this cross-sectional study clearly demonstrates
that the symptoms of DM2 greatly impact patients’ self-
reported health status.
Although DM2 and DM1 are usually considered neu-
romuscular disorders, the results of our study reﬂect their
multisystem character. The low scores on both physical and
mental health scales in the DM2 and DM1 patients in
comparison to the general population are in contrast with
results from previous studies on health status in more
restricted neuromuscular disorders, including non-dystro-
phic myotonias, inclusion body myositis, late-onset Pompe
disease, and immune-mediated polyneuropathies [10, 18,
19, 24]. In these neuromuscular diseases, although low
scores were found on the physical health scales, mental
health scores remained relatively high. Preserved high
mental scores in chronic disorders have been explained by
the fact that patients’ limitations in daily activities develop
over a long period. Over time, patients may adapt to their
situation and adjust their expectations, priorities and even
redeﬁne concepts related to mental health aspects of quality
of life, leading to the so called response shift [25, 26]. It
may well be possible that in DM2 and DM1, in which
cognitive impairment such as frontal lobe dysfunction and
an avoidant personality trait have been reported, adaptive
coping behavior is reduced or even not present, in contrast
to other disabling neuromuscular disorders [27, 28].
Cognition in terms of overall intelligence does not seem
to be impaired in DM2 [29]. The ability to complete this
self report questionnaire in a reliable and valid manner
was, therefore, present in DM2 patients. In addition, all
DM2 and DM1 patients who participated in the current
study had been diagnosed at least 1 year prior to the study,
so it is unlikely that the observed lower scores on vitality,
social functioning, and role limitations due to emotional
problems could be attributed to a reactive depression. Our
health status results in DM1 are corroborated by previous
research in which health status was measured with the SF-
36 in a group of 322 adult-onset DM1 patients [11]. Aside
from a difference in age between the present DM1 group
and the one reported by Kalkman (mean age: 52.8 years vs.
43.0 years respectively) results are comparable; all physi-
cal and mental health scores, except for the score of bodily
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123pain, were lower than those of the general population. Pain
was not evaluated in that study, but fatigue was correlated
with a lower reported health status in physical and social
functioning.
Compared to the general population, the differences in
SF-36 scores of DM2 patients was most profound for the
physical functioning scale [adjusted mean score of DM2
patients 43.5 (±21.1) vs. 82.6 (±19.7) of the general
population]. The DM2 score on the mental health scale was
the only SF-36 score not signiﬁcantly (p = 0.06) lower
compared to the Dutch normative data [adjusted mean 69.9
(±18.6) vs. 76.4 (±17.4) of the general population].
However, the outcome in DM2 is comparable to SF-36
mental health scores of two other samples with clearly
deﬁned chronic health conditions, namely migraine and
cancer patients (SF-36 mental health score 72.0 and 68.0
respectively) [15].
In DM2, age did not correlate with any of the SF-36
scales. This lack of correlation between age and health
status may be an indication that the symptoms of DM2 are
relatively stable over the lifespan. There was a positive
correlation between age of onset and the bodily pain scale
of the SF-36, indicating more bodily pain in patients whose
symptoms began at a younger age and conversely, less
bodily pain in patients whose symptoms began at an older
age. This implies that there may be a tendency for pain to
worsen over time in DM2. However, future research should
investigate these associations in the context of a prospec-
tive design.
In contrast, in DM1, age was strongly associated with
age of onset. This strong correlation, showing that older
patients in this sample had a later age of onset and
younger patients had an early age of onset, underscores
the shortened life expectancy associated with DM1. Age
in DM1 was highly associated with more impairments in
functioning and more body pain (p\0.04 on six scales),
underscoring the progressive nature of this disease. These
DM1 results are corroborated by previous research of us
and others. In the previously mentioned study on health
status in DM1 patients, similar associations were found
between age and SF-36 scores [11]. As also that study
had a cross-sectional design, the need for future longi-
tudinal research exits. In contrast, recent data in non-
dystrophic myotonic syndromes showed no correlation
between age and SF-36 scores, indicating that age did
not appear to play a role in health status [10]. Taken
together, these results again underscore the progres-
sive nature and shortened life expectancy in DM1 in
comparison to DM2 and non-dystrophic myotonic
syndromes.
In DM2, age did not correlate with pain, as measured
with VAS, or fatigue, as measured with CIS, again indi-
cating that the symptoms of DM2 may remain somewhat
stable over the lifespan. There was a signiﬁcant correlation
in DM2 between increased pain and lower levels of mental
health. Also, fatigue was negatively correlated to the scales
of vitality, general health and role functioning-physical. Of
course, one cannot infer causality on the basis of correla-
tions alone. However, both pain and fatigue appear to be
related to a decrease of health status in DM2. Pain is a
chronic symptom in DM2 and the observed association
between pain and mental health underscores the need to
identify and provide effective pain treatments for DM2
patients [6].
Some mention should be made of potential limitations of
this study. First, in eight families with DM2, several
members were evaluated. Shared genetic cofactors or rec-
ognized behavioral biasing could have inﬂuenced pain, and
data on physical, psychological and social functioning.
Second, because DM2 is, in general, more likely to be
under diagnosed than DM1, the participating DM2 patients
may be more representative of the severe end of the DM2
disease spectrum, leading to lower physical and functional
scores. Third, by studying the Dutch DM2 population, this
study does not take potential cultural differences (e.g. the
Netherlands vs. United States) into account. However,
evidence suggests that cultural differences do not play a
role in health status in neuromuscular disorders [19, 30].
Fourth, despite the solidity of our nationwide ﬁndings, it
should be noted that we did not evaluate the clinimetric
properties of the SF-36 in these speciﬁc patient popula-
tions, an omission that future research in this area could
address.
Despite these limitations, the comprehensiveness of the
SF-36 may help to increase physicians’ awareness, by
providing information on health status in patients with
DM2, besides the traditional investigation of symptoms,
signs and laboratory studies.
In summary, the current study shows the impact of DM2
on a patients’ physical, psychological and social func-
tioning is signiﬁcant and as high as in adult-onset DM1
patients. From the perspective of health-related quality of
life, DM2 should, therefore, not be considered a benign
disease. Pain and fatigue are correlated to a lower reported
health status. Management of DM2 patients should include
screening for pain and fatigue. Symptomatic treatment of
these two symptoms may decrease disease impact and
improve health status in DM2, even if the disease itself
cannot be treated. There remains a need for prospective
follow-up studies assessing the natural course of DM2 in
relation to health status, fatigue and pain.
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